Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • Nurse Well-Being
    • Drug Reference Sheets
    • ONS Congress
    • Specific Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    cozy hospital room with bed and computer
    Interprofessional Issues
    Novel, Interprofessional Approach Enhances Bed Assignments for Individuals on Antineoplastic Drugs in a Hospital Setting
    August 22, 2024
    hand touching futuristic screen that represents artificial intelligence
    Nurse Empowerment
    How AI Can Support Oncology Nurses’ Spirit of Inquiry
    August 15, 2024
    person with brown clothes holding patient's hand in support on hospital bed
    Nurse Empowerment
    Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession
    July 04, 2024
    publish with ONS Voice
    Nursing Professional Development
    Publish Your First Article With ONS Voice
    March 19, 2024
    A family of nurses
    Nurse Well-Being
    When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places
    March 07, 2024
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer
    Cancer Research

    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer

    Sotorasib offers a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-variant non-small cell lung cancer, according to the results of a clinical trial that led to the therapy’s U.S. Food and Drug Administration (FDA) approval. The researchers reported the findings in the New England Journal of Medicine.

    November 24, 2021
    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance
    Cancer Research

    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance

    Novobiocin, an antibiotic discovered during the 1950s, may be a potential second-line therapy for patients whose tumors have become resistant to poly (ADP-ribose) polymerase (PARP) inhibitors, researchers reported in Nature Cancer. The finding may open up new options for patients with BRCA-variant disease such as breast, ovarian, pancreatic, and prostate cancer.

    November 17, 2021
    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer
    Prostate Cancer

    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer

    Among patients with metastatic, castration-resistant prostate cancer, treatment with the experimental 177Lu-PSMA-617 radiopharmaceutical, along with other standard treatments, improved survival by four months over treatment with standard therapies alone, researchers reported in the New England Journal of Medicine. The therapy targets the PMSA protein and may one day be an option when other treatments have failed.

    November 10, 2021
    Cultural Humility Is a Nursing Clinical Competency
    Cultural Competency

    Cultural Humility Is a Nursing Clinical Competency

    To confront the disparities that minority populations face in health care, organizations across the United States are recognizing that cultural humility is a clinical competency. Implicit and explicit bias are part of human nature, but prioritizing cultural humility as a foundation, diversifying the workforce, and engaging in education and training can help providers overcome those tendencies and achieve patient-centered care.

    November 09, 2021
    Clinical Full-Body Skin Examination Identifies Twice the Number of Cancers
    Melanoma

    Clinical Full-Body Skin Examination Identifies Twice the Number of Cancers

    A dermatologist-performed total-body skin examination (TBSE) identifies more than two times the number of skin cancers than patients or other providers discovered, researchers reported in the International Journal of Women’s Dermatology. The cancers may otherwise have gone undiagnosed, leading to later-stage disease and poorer outcomes.

    November 03, 2021
    Combination Immunotherapy May Further Increase Melanoma Survival Length
    Melanoma

    Combination Immunotherapy May Further Increase Melanoma Survival Length

    Using two agents that target two different receptors more than doubles length of survival for advanced melanoma than a single agent alone, researchers reported at the 2021 American Society of Clinical Oncology annual meeting.

    October 27, 2021
    New Study Supports CRC Screening for People Older Than 75
    Cancer Screening

    New Study Supports CRC Screening for People Older Than 75

    Colorectal cancer (CRC) screening may be beneficial for certain patients aged 75–85, according to findings from a new study. The researchers reported the results in JAMA Oncology.

    October 20, 2021
    HER2 Therapies May Be Effective in a Variety of Solid Tumors
    Research

    HER2 Therapies May Be Effective in a Variety of Solid Tumors

    Researchers have found that 2%–3% of all solid tumors overexpress or amplify HER2 protein that may be a target for drugs such as pertuzumab and trastuzumab, particularly in KRAS-variant disease. They presented their findings during the 2021 American Society of Clinical Oncology annual meeting.

    October 13, 2021
    It Takes a Team to Confront Moral Distress
    Compassion Fatigue

    It Takes a Team to Confront Moral Distress

    Unbearable levels of stress, burnout, frustration, disappointment, and even fear are plaguing today’s healthcare providers more than ever before. But for oncology nurses, moral distress and compassion fatigue have always been in the background when caring for patients with a serious illness.

    October 12, 2021
    Radioprotectant May Also Be a Radiobooster
    Radiation Therapy

    Radioprotectant May Also Be a Radiobooster

    Initially studied for its radioprotective effects on healthy cells, avasopasem may also increase cancer cells’ response to radiation treatment, researchers reported in Science Translational Medicine.

    October 06, 2021
    Proton Pump Inhibitors May Boost Radiation’s Effects
    Radiation Therapy

    Proton Pump Inhibitors May Boost Radiation’s Effects

    September 29, 2021
    Antibiotics May Reduce Checkpoint Inhibitor Efficacy
    Research

    Antibiotics May Reduce Checkpoint Inhibitor Efficacy

    Using antibiotics during treatment with immune checkpoint inhibitors may limit the therapy’s effect, according to study results published in the American Journal of Clinical Oncology.

    September 22, 2021
    This Is Why Red Meat Increases Colorectal Cancer Risk
    Cancer Research

    This Is Why Red Meat Increases Colorectal Cancer Risk

    Frequent red and processed meat consumption leaves a specific pattern of DNA damage in colorectal cells that contributes to the formation of tumors, researchers reported in study findings published in Cancer Discovery.

    September 15, 2021
    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities
    Cancer Research

    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

    When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

    September 14, 2021
    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes
    Research

    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes

    TP53 and MYOD1 variants are associated with more aggressive forms of rhabdomyosarcoma, a rare childhood cancer, and poorer outcomes, according to the results of the largest international genomic profiling study of the disease. The findings, which were published in the Journal of Clinical Oncology, have implications for somatic biomarker testing to guide tailored treatment approaches.

    September 09, 2021
    BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia
    Research

    BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia

    Ibrutinib produces durable disease control for patients with high-risk hairy cell leukemia, a rare cancer, who have relapsed and for whom standard purine analogues are not a feasible therapeutic option, according to study results published in Blood.

    September 08, 2021
    Testicular Cancer Treatment and Survival Rates Are Improving
    Cancer Research

    Testicular Cancer Treatment and Survival Rates Are Improving

    Progression-free and overall survival rates for patients with metastatic testicular cancer have significantly grown since 1990, researchers reported in the Journal of Clinical Oncology.

    August 25, 2021
    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS
    Genetics & Genomics

    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS

    When compared to conventional testing on the same samples from patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), whole-genome sequencing–based testing detected the same abnormalities—and new genetic information in about a quarter of patients, potentially changing treatment selection for more than half of those patients, researchers said in the New England Journal of Medicine.

    August 18, 2021
    Researchers Tie More Cancers, Mortality to NF1 Disorders
    Cancer Research

    Researchers Tie More Cancers, Mortality to NF1 Disorders

    The genetic disorder neurofibromatosis type 1 (NF1) is linked to the development of and mortality for more types of cancer than previously identified, researchers reported in results from a new study. They published the findings in JAMA Network Open.

    August 11, 2021
    Coaching Roles Give Nurses New Avenues to Provide Patient-Centered Care
    Oncology Nurse Influence

    Coaching Roles Give Nurses New Avenues to Provide Patient-Centered Care

    Nurses don’t always have to venture beyond the bedside for unique career change opportunities. Always innovating and evolving, the profession identifies new roles for clinical practice nurses to meet patients’ needs.

    August 10, 2021
    Heart Failure May Increase Risk for Certain Cancers
    Research

    Heart Failure May Increase Risk for Certain Cancers

    Patients with heart failure have a 75% increased risk of developing cancer, researchers reported in ESC Heart Failure. And cancer incidence rates were even higher for specific disease sites.

    August 04, 2021
    New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers
    Immunotherapy

    New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers

    Scientists created a new cancer immunotherapy approach that uses a new type of CAR T cells to stimulate an immune response against cells that are missing one gene copy. They reported their findings in Proceedings of the National Academy of Sciences.

    July 28, 2021
    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance
    Cancer Research

    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

    A protein called AMBRA1 may be to blame for tumor resistance to CDK4/6 inhibitors, according to results from international teams of researchers that were reported in Nature.

    July 21, 2021
    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship
    Research

    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

    More than 40% of patients with melanoma treated with nivolumab or pembrolizumab experience persistent long-term immune-related adverse events (irAEs) for at least 1.5 years, researchers reported in JAMA Oncology.

    July 14, 2021
    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity
    Research

    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

    Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.

    July 13, 2021
    • First page « First
    • Previous page
    • …
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Current page 9
    • Page 10
    • Page 11
    • Page 12
    • Page 13
    • …
    • Next page
    • Last page Last »

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    content['#byline_profile'].image_alt_text
    Elisa Becze BA, ELS, Editor
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Contact Us
  • Advertising
  • Newsroom
  • Conferences
  • RSS Feed
  • Sitemap
  • Legal Notices

    • Subscribe to ONS Voice Updates

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2024 Oncology Nursing Society
    Back to Top ▲